Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Hernando

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2022
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with CholangiocarcinomaHelena Verdaguer, Tamara Saurí, Daniel Alejandro Acosta, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Cell Reports. Medicine|March 21, 2025
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancerMaria Balaguer-Montero, Adrià Marcos Morales, Marta Ligero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
The Oncologist|December 10, 2020
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?Elettra Merola, Teresa Alonso Gordoa, Panpan Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursJorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Therapeutic Advances in Endocrinology and Metabolism|April 1, 2026
Clinical characteristics, diagnosis, and treatment of Cushing's syndrome: analysis of a multicenter registry in Antioquia, ColombiaWilfredo Antonio Rivera-Martínez, María Johana Ramírez Castaño, Stefanía Cruz Calderón, et al.
Endocrine-Related Cancer|April 11, 2025
Spanish consensus on the diagnosis and management of adrenocortical carcinomaMarta Araujo-Castro, Cristina Álvarez-Escola, Ana Casteràs, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2026
Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)Jorge Hernando, Carlos Lopez, Alejandro Garcia-Alvarez, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2022
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with CholangiocarcinomaHelena Verdaguer, Tamara Saurí, Daniel Alejandro Acosta, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Cell Reports. Medicine|March 21, 2025
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancerMaria Balaguer-Montero, Adrià Marcos Morales, Marta Ligero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
The Oncologist|December 10, 2020
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?Elettra Merola, Teresa Alonso Gordoa, Panpan Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursJorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Therapeutic Advances in Endocrinology and Metabolism|April 1, 2026
Clinical characteristics, diagnosis, and treatment of Cushing's syndrome: analysis of a multicenter registry in Antioquia, ColombiaWilfredo Antonio Rivera-Martínez, María Johana Ramírez Castaño, Stefanía Cruz Calderón, et al.
Endocrine-Related Cancer|April 11, 2025
Spanish consensus on the diagnosis and management of adrenocortical carcinomaMarta Araujo-Castro, Cristina Álvarez-Escola, Ana Casteràs, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2026
Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)Jorge Hernando, Carlos Lopez, Alejandro Garcia-Alvarez, et al.
Pageof 10